Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades

Page view(s)
16
Checked on Sep 19, 2024
Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades
Title:
Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades
Journal Title:
Antiviral Research
Keywords:
Publication Date:
04 May 2014
Citation:
Tze-Minn Mak, Brendon J. Hanson, Yee-Joo Tan, Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza A H5N1 clades, Antiviral Research, Volume 107, July 2014, Pages 76-83, ISSN 0166-3542, http://dx.doi.org/10.1016/j.antiviral.2014.04.011. (http://www.sciencedirect.com/science/article/pii/S016635421400117X)
Abstract:
The persistent evolution and circulation of highly pathogenic avian influenza H5N1 viruses pose a serious threat to global heath and hamper pandemic preparedness through conventional vaccine strategies. Combination passive immunotherapy using non-competing neutralizing antibodies has been proposed as a viable alternative to provide broad protection against drift variants. This necessitates the pre-pandemic production and characterization of potently neutralizing monoclonal antibodies (MAbs). One such antibody, MAb 9F4 was shown to provide heterologous protection against multiple H5N1 clade viruses, including one of the recently designated subclades, namely 2.3.4, through binding to a novel epitope, warranting its further development and characterization as a therapeutic candidate. In this study, the conversion of MAb 9F4 from mouse IgG2b to mouse-human chimeric (xi) IgG1 and IgA1 was achieved. These chimeric MAb versions were found to retain high degrees of binding and neutralizing activity against H5N1. The demonstration that xi-IgA1-9F4 retains a fairly high level of neutralizing activity, which is ∼10-fold lower than the corresponding xi-IgG1 isotype, suggests that this MAb could be further developed and engineered for intranasal administration.
License type:
PublisherCopyrights
Funding Info:
Description:
ISSN:
0166-3542
Files uploaded:

File Size Format Action
1-s20-s016635421400117x-main.pdf 1.61 MB PDF Open